Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06436703 · ClinicalTrials.gov registry record · Phase 1
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,202
- Enrollment target
NCT06436703 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 1,202 participants.
The verdict
NCT06436703, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,202 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid. Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat. The study is seeking for participants who: * are at least 18 years of age * have not received an influenza vaccine within the last 6 months * are generally healthy This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC). All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm: * 1 of the modRNA influenza vaccines that is being studied; or * an approved influenza vaccine approved for use in their respective age group. Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.
Interventions
- BIOLOGICAL Influenza ModRNA Vaccine
- BIOLOGICAL Quadrivalent Influenza Vaccine (QIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,202 participants |
| Start Date | 2024-05-23 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06436703
The ClinicalTrials.gov registry entry for NCT06436703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Influenza ModRNA Vaccine is the first listed.
NCT06436703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06436703 about?
NCT06436703 is a clinical study titled "A Study About Modified RNA Vaccines Against Influenza in Healthy Adults". The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RN...
What is the current status of trial NCT06436703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,202 participants. The study started on 2024-05-23. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT06436703?
The interventions under investigation include: Influenza ModRNA Vaccine (BIOLOGICAL), Quadrivalent Influenza Vaccine (QIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06436703?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.